BIOMAD NL study
- Conditions
- <p>Atopic dermatitis, atopic eczema</p>
- Registration Number
- NL-OMON21253
- Lead Sponsor
- Amsterdam UMC, Academic Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 110
Patient has a diagnosis of AD, based on the U.K. working party’s diagnostic criteria;
-Starts with any type of phototherapy (e.g. UVB) or systemic immunomodulating therapy (e.g. ciclosporin, systemic glucocorticosteroids, azathioprine, methotrexate, mycophenolic acid, dupilumab);
-Has voluntarily signed and dated an informed consent prior to any study related procedure or has a legal representative to do so and is willing to comply with the requirements of this study protocol.
-Patient uses only (systemic) antibiotics or antihistamines;
-Patient starts with systemic immunomodulating therapy for another indication than atopic dermatitis;
-Insufficient understanding of the study by the patient or parent/legal representative;
-Patient does not participate in the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The combined efforts of BIOMAP will support the definition of endotypes, i.e. a more precise disease classification, a definition of biomarkers enabling patient stratification and patient-directed care strategies, and the early identification of the most suitable therapy for every patient. They will also stimulate future research on mechanisms and innovative treatments directed at endotype components.</p>
- Secondary Outcome Measures
Name Time Method <p>-</p>